Tarsus Pharmaceuticals 12-Month Price Target Cut to $98.89
The revised target implies 37% upside.
Related stories
AstraZeneca Q3 Adjusted Earnings and Revenue Rise, Outlook Reaffirmed
M impact | EQUITY | Oct 30, 2026, 10:07 AM UTC
BrightSpring Health Reports Third-Quarter Results, Raises 2026 Guidance
M impact | EQUITY | Oct 30, 2026, 10:02 AM UTC
Reddit Reports Q3 2026 Revenue of $894.96M, Net Income of $283.26M
Reddit reported revenue up 53% year over year to $894.96 million, net income up 74.1% to $283.26 million and diluted EPS up 75% to $1.40. Advertising revenue growth and stronger ad
M impact | EQUITY | Oct 30, 2026, 10:01 AM UTC
US Midterms, Earnings and Jobs Report Set to Test AI-Wary Market
US midterm elections, a heavy slate of corporate earnings and the monthly jobs report will test stock investors next week after setbacks in the AI trade.
M impact | EQUITY | Oct 30, 2026, 10:00 AM UTC
European session market picture: S&P 500 -1.02%, Nasdaq 100 -2.29%; EUR/USD +0.19%, WTI +2.02%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 1.02 percent, Nasdaq futures is down 2.29 percent, Dow futures is up 0.02 percent and Russell futures is
M impact | EQUITY | Oct 30, 2026, 10:00 AM UTC
Intel outlook raises new doubts about earnings recovery
A Street View report says Intel's outlook has raised new questions about its earnings recovery, citing weakness in the PC market, manufacturing problems and expansion costs.
M impact | EQUITY | Oct 30, 2026, 09:58 AM UTC